Tailored Antiplatelet Therapy Following PCI
Completed · Phase 4
Conditions studied: Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
In brief
Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some studies have suggested that patients who have a certain genetic liver enzyme abnormality (known as cytochrome P450 2C19 \[CYP2C19\] \*2 or \*3 allele) may have a reduced ability to activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought that perhaps people who have a coronary stent procedure may have this genetic liver enzyme abnormality. There is a research genetic test available to determine whether or not someone has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is not dependent on the CYP2C19 liver enzyme for its activation and hence in poor clopidogrel metabolizers, alternative drugs like Ticagrelor have been recommended for use as an anti-platelet agent after PCI. The purpose of this study is to determine if genetic testing can identify the best anti-platelet therapy, for patients who undergo a coronary stent placement and do not activate clopidogrel very well.
Key facts
- Study ID
- NCT01742117
- Run by
- Mayo Clinic
- People needed
- 5276
- Starts
- 2013-05-01
- Expected to finish
- 2020-10-31
- Last updated by the study team
- 2021-11-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States
- Sharp HealthCare — San Diego, California, United States
- Zuckerberg San Francisco General — San Francisco, California, United States
- Mayo Clinic in Florida — Jacksonville, Florida, United States
- NCH Heart Institute — Naples, Florida, United States
- NorthShore University Health System — Evanston, Illinois, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- St. Elizabeth Healthcare — Crestview Hills, Kentucky, United States
- Henry Ford Hospital — Detroit, Michigan, United States
- Essentia Institute of Rural Health — Duluth, Minnesota, United States
- Minneapolis Heart Institute — Minneapolis, Minnesota, United States
- University of Minnesota — Minneapolis, Minnesota, United States
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
- The University of Mississippi Medical Center — Jackson, Mississippi, United States
- Albany Medical College — Albany, New York, United States
- The Feinstein Institute for Medical Research — Manhasset, New York, United States
- Winthrop University Hospital — Mineola, New York, United States
- New York University Langone Medical Center — New York, New York, United States
- Columbia University Medical Center — New York, New York, United States
- Cardiology Associates of Schenectady — Schenectady, New York, United States
- Rhode Island Hospital — Providence, Rhode Island, United States
- The Miriam Hospital — Providence, Rhode Island, United States
- Greenville Health System — Greenville, South Carolina, United States
- MHS, Eau Claire — Eau Claire, Wisconsin, United States
- Mayo Clinic Health System — La Crosse, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.